LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Are Behçet's disease patients with Budd-Chiari at increased risk for the development of pulmonary hypertension?

    Ekici, Mustafa / İleri, Serez / Ünaldı, Erdinç / Bayram, Gözde Sevgi Kart / Kılıç, Levent / Akdoğan, Ali

    Rheumatology (Oxford, England)

    2024  

    Language English
    Publishing date 2024-02-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keae067
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Case report: Pulmonary endarterectomy in Takayasu arteritis patient with group IV pulmonary hypertension: A rare clinical scenario.

    Unaldi, Erdinc / Firlatan, Busra / Duzgun, Selin Ardali / Koca, Suleyman Serdar / Yildizeli, Bedrettin / Akdogan, Ali

    International journal of rheumatic diseases

    2023  Volume 27, Issue 3, Page(s) e15119

    MeSH term(s) Humans ; Hypertension, Pulmonary/diagnosis ; Hypertension, Pulmonary/etiology ; Hypertension, Pulmonary/surgery ; Takayasu Arteritis/complications ; Takayasu Arteritis/diagnosis ; Takayasu Arteritis/surgery ; Lung ; Diagnosis, Differential
    Language English
    Publishing date 2023-12-13
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 2426924-4
    ISSN 1756-185X ; 1756-1841
    ISSN (online) 1756-185X
    ISSN 1756-1841
    DOI 10.1111/1756-185X.15119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6098: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study.

    Bilgin, Emre / Duran, Emine / Ünaldı, Erdinç / Kalyoncu, Umut / Kiraz, Sedat / Ertenli, İhsan

    Rheumatology (Oxford, England)

    2022  Volume 61, Issue 9, Page(s) e267–e269

    MeSH term(s) Etanercept/adverse effects ; Herpes Zoster/chemically induced ; Herpes Zoster/epidemiology ; Herpesvirus 3, Human ; Humans ; Neoplasms ; Piperidines/adverse effects ; Pyrimidines ; Pyrroles/adverse effects
    Chemical Substances Piperidines ; Pyrimidines ; Pyrroles ; tofacitinib (87LA6FU830) ; Etanercept (OP401G7OJC)
    Language English
    Publishing date 2022-04-08
    Publishing country England
    Document type Observational Study ; Letter
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keac226
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry.

    Duran, Emine / Ozturk, Zeynep Ozge / Bilgin, Emre / Büyükaşık, Yahya / Dizdar, Omer / Yardimci, Gozde Kubra / Farisogullari, Bayram / Özsoy, Zehra / Ayan, Gizem / Uzun, Gullu Sandal / Ekici, Mustafa / Unaldi, Erdinc / Kilic, Levent / Akdoğan, Ali / Karadag, Omer / Bilgen, Şule Apraş / Kiraz, Sedat / Kalyoncu, Umut / Ertenli, Ali Ihsan

    Rheumatology and therapy

    2023  Volume 10, Issue 4, Page(s) 969–981

    Abstract: Introduction: This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population.: Methods: HUR-BIO ( ... ...

    Abstract Introduction: This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population.
    Methods: HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single-center biological disease-modifying anti-rheumatic drug (bDMARD) registry since 2005. Patients with IA, including rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who had at least one visit after the TNFi were screened from 2005 to November 2021. Standardized incidence rates (SIR) were calculated after adjustment for age and gender and compared with the 2017 Turkish National Cancer Registry (TNCR).
    Results: Of the 6139 patients registered in the HUR-BIO, 5355 used any TNFi at least once. The median follow-up duration was 2.6 years for patients receiving TNFi. Thirteen patients developed a HM on follow-up. In these patients, the median age at the IA onset was 38 (range, 26-67), and the median age at the HM diagnosis was 55.5 (range, 38-76). Patients using TNFi had an increased HM incidence (SIR 4.23, 95% confidence interval (CI) 2.35-7.05). Ten patients with HM were under 65 years of age. In this group, there was a higher incidence of HM in both men (SIR 5.15, 95% CI 1.88-11.43) and women (SIR 4.76, 95% CI 1.74-10.55).
    Conclusions: The risk of HMs in inflammatory arthritis patients receiving TNFi was four times higher than in the general Turkish population.
    Language English
    Publishing date 2023-06-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2783278-8
    ISSN 2198-6584 ; 2198-6576
    ISSN (online) 2198-6584
    ISSN 2198-6576
    DOI 10.1007/s40744-023-00563-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Factors that predict development of chronic kidney disease in patients with rheumatoid arthritis receiving biologic DMARDs and mortality rates.

    Sandal Uzun, Güllü / Taghiyeva, Arzu / Çakır, İbrahim Y / Moral, Kenan / Yardımcı, Gözde Kübra / Bölek, Ertuğrul Ç / Farisoğulları, Bayram / Duran, Emine / Ayan, Gizem / Özsoy, Zehra / Ekici, Mustafa / Unaldı, Erdinç / Germe, Şerife A / Fırlatan, Büşra / Kart-Bayram, Gözde S / Bilgin, Emre / Kılıç, Levent / Karadağ, Ömer / Akdoğan, Ali /
    Bilgen, Şule A / Kiraz, Sedat / Ertenli, Ali Ihsan / Kalyoncu, Umut

    International journal of rheumatic diseases

    2023  Volume 27, Issue 1, Page(s) e14967

    Abstract: Objectives: We aimed to determine the choice of biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/ts-DMARDs), factors associated with the development of chronic kidney disease (CKD), and mortality in RA patients with CKD receiving b/ ... ...

    Abstract Objectives: We aimed to determine the choice of biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/ts-DMARDs), factors associated with the development of chronic kidney disease (CKD), and mortality in RA patients with CKD receiving b/ts-DMARDs.
    Methods: Two thousand one hundred forty-one RA (79.4% female) patients were included in the analysis from the HUR-BIO prospective registry. Patients were divided into the CKD group and the non-CKD group. Age and gender-matched patients were selected from the non-CKD group, and then three main groups were determined. CKD was staged according to the glomerular filtration rate criteria. The clinical characteristics of the patients, disease activities, treatment choices, drug retention rate, and mortality rates were compared between the groups.
    Results: CKD was detected in 90/2141 (4.2%) RA patients on b/ts-DMARDs. Forty patients (2.3%) developed CKD during follow-up after the initiation of b/ts-DMARDs. In the CKD group, anti-TNF agents were chosen as the first-line b/ts-DMARDs therapy in 64.4% of patients, with etanercept leading in 31 (34.4%) patients. In multivariate analysis, age at the start of treatment, DAS-28-ESR at last visit, amyloidosis, hypertension, and history of smoking were the factors associated with the development of CKD in RA patients receiving b/ts-DMARDs. The mortality rate in RA-CKD patients until the onset of the pandemic was 15.41 per 1000 patient years, whereas it was 85.9 per 1000 patient years after the pandemic.
    Conclusion: Comorbidities and control of disease activity are critical in the development of CKD in RA patients receiving b/ts-DMARDs. While there was no significant difference in mortality rate between CKD and non-CKD patients, the overall mortality rate increased after the COVID-19 pandemic duration in both groups.
    MeSH term(s) Humans ; Female ; Male ; Pandemics ; Tumor Necrosis Factor Inhibitors/adverse effects ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/epidemiology ; Biological Products/adverse effects ; Renal Insufficiency, Chronic/diagnosis ; Renal Insufficiency, Chronic/epidemiology
    Chemical Substances Tumor Necrosis Factor Inhibitors ; Antirheumatic Agents ; Biological Products
    Language English
    Publishing date 2023-12-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 2426924-4
    ISSN 1756-185X ; 1756-1841
    ISSN (online) 1756-185X
    ISSN 1756-1841
    DOI 10.1111/1756-185X.14967
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6098: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top